MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study

被引：1
|
作者：
Ghobrial, Irene M. [1 ,2 ]
Siegel, David [3 ]
Vij, Ravi [4 ]
Wolf, Jeffrey L. [5 ]
Berdeja, Jesus G. [6 ]
Matous, Jeffrey V. [7 ]
Lipman, Peter [8 ]
Patel, Chirag [8 ]
Le, Trinh [9 ]
Rommel, Christian [9 ]
Berk, Gregory [8 ]
机构：
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA
[3] Hackensack Univ Med Ctr, Hackensack, NJ USA
[4] Washington Univ Sch Med, Div Oncol, Dept Med, St Louis, MO USA
[5] Univ Calif San Francisco, San Francisco, CA 94143 USA
[6] Sarah Cannon Res Inst, Nashville, TN USA
[7] Colorado Blood Canc Inst, Denver, CO USA
[8] Millennium Pharmaceut Inc, Cambridge, MA USA
[9] Intellikine LLC, La Jolla, CA USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.4038.4038
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4038
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Durable Responses After Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory (R/R) Aggressive Non-Hodgkin's Lymphoma (a-NHL): Results From An International Phase 2 Study (CC-5013-NHL-003).
    Witzig, Thomas E.
    Vose, Julie M.
    Zinzani, Pier Luigi
    Reeder, Craig B.
    Buckstein, Rena
    Polikoff, Jonathan
    Guo, Pingshan
    Pietronigro, Dennis
    Ervin-Haynes, Annette
    Czuczman, Myron S.
    BLOOD, 2009, 114 (22) : 668 - 669
  • [32] PHARMACOKINETICS (PK) OF ANTI-622 AND ANTI-CD79B ANTIBODY DRUG CONJUGATES (ADCS) IN RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA (NHL) PATIENTS: RESULTS FROM PHASE I DOSE-ESCALATION STUDIES
    Lu, D.
    Agarwal, P.
    Prabhu, S.
    Nazzal, D.
    Dere, R.
    Saad, O.
    Chu, Y.
    Li, D.
    Girish, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S77 - S78
  • [33] OPROZOMIB (OPZ) AND DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED RESULTS FROM DOSE ESCALATION IN A PHASE 1B/2, MULTICENTER, OPEN-LABEL STUDY
    Hari, P.
    Shain, K. H.
    Voorhees, P.
    Gabrail, N.
    Abidi, M.
    Zonder, J.
    Boccia, R.
    Richardson, P. G.
    Neuman, L.
    Wong, H.
    Dixon, S.
    Prada, C. P.
    HAEMATOLOGICA, 2015, 100 : 254 - 255
  • [34] A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM)
    Yap, Timothy A.
    Winter, Jane N.
    Leonard, John P.
    Ribrag, Vincent
    Constantinidou, Anastasia
    Giulino-Roth, Lisa
    Michot, Jean-Marie
    Khan, Tariq A.
    Horner, Thierry
    Carver, Jennifer
    Dumetrescu, Teodora Pene
    He, Zangdong
    McCabe, Michael T.
    Creasy, Caretha L.
    Dhar, Arindam
    Carpenter, Christopher
    Johnson, Peter M.
    BLOOD, 2016, 128 (22)
  • [35] Umbralisib, a PI3Kδ/CK1ε Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL Trial
    Ghosh, Nilanjan
    Zinzani, Pier Luigi
    Samaniego, Felipe
    Jurczak, Wojciech
    Derenzini, Enrico
    Reeves, James A.
    Knopinska-Posluszny, Wanda
    Cheah, Chan Y.
    Phillips, Tycel
    Lech-Maranda, Ewa
    Cheson, Bruce
    Caimi, Paolo
    Grosicki, Sebastian
    Leslie, Lori A.
    Chavez, Julio C.
    Fonseca, Gustavo
    Babu, Sunil
    Hodson, Daniel J.
    Shao, Spencer H.
    Burke, John M.
    Sharman, Jeff P.
    Law, Jennie Y.
    Pagel, John M.
    Miskin, Hari P.
    Sportelli, Peter
    O'Connor, Owen A.
    Weiss, Michael S.
    Fowler, Nathan H.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S404 - S404
  • [36] UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL, DOSE-ESCALATION PHASE 1B/2 STUDY OF SINGLE-AGENT OPROZOMIB (OPZ) IN PATIENTS (PTS) WITH HEMATOLOGIC MALIGNANCIES, INCLUDING MULTIPLE MYELOMA (MM)
    Vij, R.
    Savona, M.
    Siegel, D.
    Kaufman, J. L.
    Badros, A.
    Ghobrial, I.
    Paner, A.
    Jagannath, S.
    Jakubowiak, A.
    Mikhael, J.
    Kapoor, P.
    Neuman, L.
    Obreja, M.
    Berdeja, J.
    HAEMATOLOGICA, 2015, 100 : 251 - 251
  • [37] Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial
    Zinzani, Pier Luigi
    Samaniego, Felipe
    Jurczak, Wojciech
    Ghosh, Nilanjan
    Derenzini, Enrico
    Reeves, James A.
    Knopinska-Posluszny, Wanda
    Cheah, Chan Yoon
    Phillips, Tycel J.
    Lech-Maranda, Ewa
    Cheson, Bruce D.
    Caimi, Paolo F.
    Grosicki, Sebastian
    Leslie, Lori A.
    Chavez, Julio C.
    Fonseca, Gustavo A.
    Babu, Sunil
    Hodson, Daniel J.
    Shao, Spencer H.
    Burke, John M.
    Sharman, Jeff P.
    Law, Jennie Y.
    Pagel, John M.
    O'Connor, Owen A.
    Miskin, Hari P.
    Sportelli, Peter
    Weiss, Michael S.
    Fowler, Nathan H.
    BLOOD, 2020, 136
  • [38] Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε, Demonstrates Clinical Activity in Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase 2 Global UNITY-NHL Trial
    Zinzani, Pier Luigi
    Samaniego, Felipe
    Jurczak, Wojciech
    Ghosh, Nilanjan
    Derenzini, Enrico
    Reeves, James A.
    Knopinska-Posluszny, Wanda
    Cheah, Chan Yoon
    Phillips, Tycel J.
    Lech-Maranda, Ewa
    Cheson, Bruce D.
    Caimi, Paolo F.
    Grosicki, Sebastian
    Leslie, Lori A.
    Chavez, Julio C.
    Fonseca, Gustavo A.
    Babu, Sunil
    Hodson, Daniel J.
    Shao, Spencer H.
    Burke, John M.
    Sharman, Jeff P.
    Law, Jennie Y.
    Pagel, John M.
    O'Connor, Owen A.
    Miskin, Hari P.
    Sportelli, Peter
    Weiss, Michael S.
    Fowler, Nathan H.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 12 - 13
  • [39] A Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: Safety and Efficacy Results from a Phase 1 Study
    Song, Yuqin
    Cai, Qingqing
    Jiang, Ming
    Zhang, Lei
    Sun, Xiuhua
    Jin, Zhengming
    Li, Lanfang
    Jing, Hongmei
    Peng, Zhigang
    Yang, Haiyan
    Qi, Junyuan
    Zhou, Hui
    Yang, Wei
    Zhou, Min
    Ji, Chunyan
    Xu, Wei
    Ding, Kaiyang
    Yu, Li
    Wang, Zheng
    Liu, Nawei
    Lou, Yejiang
    Shen, Yue
    Chen, Yi
    Tan, Fenlai
    Zhu, Jun
    BLOOD, 2023, 142
  • [40] Initial Results from a Phase 1 Dose-Escalation Study of WVT078, a BCMAxCD3 Bispecific Antibody, in Combination with WHG626, a Gamma-Secretase (GS) Inhibitor, in Patients with Relapsed and/or Refractory Multiple Myeloma
    Schjesvold, Fredrik
    Spencer, Andrew
    Cohen, Yael C.
    Ocio, Enrique M.
    Lopez-Pardo, Jordi
    Cafro, Anna Maria
    Callander, Natalie S.
    Kaufman, Jonathan L.
    Mohan, Meera
    Wermke, Martin
    Doki, Noriko
    Kan, Rebecca
    Kulec, Karolina
    Trabucco, Gina
    Ye, Stan
    Sechaud, Romain
    Quadt, Cornelia
    Chawla, Raghav
    Raab, Marc S.
    BLOOD, 2023, 142
12345